

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1. -- 8. (Canceled)

Claim 9. (Currently Amended) A compound selected from the group consisting of

ethyl 5-isopropyl-4-oxo-7-p-tolyl-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]-pyrimidine-6-carboxylate,

ethyl 5-methyl-4-oxo-7-(3-chlorophenyl)-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

ethyl 5-methyl-4-oxo-7-(2-chlorophenyl)-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

ethyl 5-methyl-4-oxo-7-(2-fluorophenyl)-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

ethyl 5-propyl-4-oxo-7-(2-chlorophenyl)-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

ethyl 5-methyl-4-oxo-7-(4-chlorophenyl)-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

methyl 5-methyl-4-oxo-7-(2-chlorophenyl)-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

methyl 5-methyl-4-oxo-7-phenyl-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

methyl 5-methyl-4-oxo-7-(2-thienyl)-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxylate,

and pharmaceutically usable ~~derivatives~~ salts of these compounds, and stereoisomers thereof, including mixtures thereof in all ratios, ~~wherein the derivatives are salts of the compound or prodrugs of the compound wherein the compound is modified with alkyl or acyl groups, sugars or oligopeptides which are rapidly cleaved in vivo to release the active ingredient compound.~~

Claim 10. -- 12. (Canceled)

Claim 13. (Previously presented) A medicament composition comprising at least one compound according to claim 9 and at least one excipient or adjuvant.

Claim 14. (Currently Amended) A method for the preparation of a medicament for the treatment of a patient suffering from a disease or disorder caused by the PDE-VII isozyme in its role in regulating the activation and degranulation of human eosinophils, which comprises bringing a compound of claim 9 into a form suitable for pharmaceutical administration.

Claims 15. -- 21. (Canceled)

Claim 22. (Previously presented) A medicament composition comprising at least one compound according to Claim 9 and at least one further medicament active ingredient.

Claim 23. (Previously presented) A kit comprising separate packs of
(a) an effective amount of a compound of claim 9,
and
(b) an effective amount of a further medicament active ingredient.

Claims 24. -- 29. (Canceled)

Claim 30. (Currently Amended) A composition comprising a compound of claim 9 together with one or more other compounds selected from the following groups:

(a) leukotriene biosynthesis inhibitors: 5-lipoxygenase (5-LO) inhibitors and 5-lipoxygenase activating protein (FLAP) antagonists selected from the group consisting of zileuton, ABT-761, fenleuton, tepoxalin, Abbott-79175, Abbott-85761, N-(5-substituted) thiophene-2-alkylsulfonamides, 2,6-di-tert-butylphenol hydrazones, Zeneca ZD-2138, SB-

210661, the pyridinyl-substituted 2-cyanonaphthafene compound L-739,010, the 2-cyanoquinoline compound L-746,530, the indole and quinoline compounds MK-591, MK-886 and BAY x 1005;

(b) receptor antagonists for the leukotrienes LTB₄, LTC₄, LTD and LTE₄ selected from the group consisting of the phenothiazin-3-one compound L-651,392, the amidino compound CGS-25019c, the ~~benzoxaolamine~~ benzoxazolamine compound ontazolast, the benzenecarboximidamide compound BIIL 284/260, the compounds zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A) and BAY x 7195;

(c) PDE IV or VII inhibitors;

(d) 5-lipoxygenase (5-LO) inhibitors; antagonists of 5-lipoxygenase activating protein (FLAP);

(e) dual inhibitors of 5-lipoxygenase (5-LO) and antagonists of platelet activating factor (PAF);

(f) leukotriene antagonists (LTRAs), ~~including LTB₄, LTC₄, LTD₄ and LTE₄~~
~~antagonists;~~

(g) antihistamine H₁ receptor antagonists, ~~including cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine and chlorpheniramine;~~

(h) gastroprotective H₂ receptor antagonists;

(i) α_1 - and α_2 -adrenoceptor agonist vasoconstrictor sympathomimetic agents administered orally or topically for decongestant use, selected from the group consisting of propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazo-

line hydrochloride and ethylnorepinephrine hydrochloride;

(j) α_1 - and α_2 -adrenoceptor agonists as listed above under (i) in combination with one or more inhibitors of 5-lipoxygenase (5-LO) as listed above under (a);

(k) anticholinergic agents, ~~including ipratropium bromide, tiotropium bromide, oxitropium bromide, pirfenidone and tiotropium bromide;~~

(l) β_1 - to β_4 -adrenoceptor agonists selected from the group consisting of metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate and pirbuterol;

(m) theophylline and aminophylline;

(n) sodium cromoglycate;

(o) muscarinic receptor (M1, M2 and M3) antagonists;

(p) COX-1 inhibitors (NSAIDs) and nitric oxide NSAIDs

(q) the COX-2 selective inhibitor rofecoxib;

(r) insulin-like growth factor type I (IGF-1) mimetics;

(s) ciclesonide;

(t) inhalation glucocorticoids with reduced systemic side effects selected from the group consisting of prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate and mometasone furoate;

- (u) tryptase inhibitors;
- (v) platelet activating factor (PAF) antagonists;
- (w) monoclonal antibodies against endogenous inflammatory entities;
- (x) IPL 576;
- (y) antitumour necrosis factor (TNF α) agents selected from the group consisting of etanercept, infliximab and D2E7;
- (z) DMARDs selected from the group consisting of leflunomide;
- (aa) TCR peptides;
- (bb) interleukin converting enzyme (ICE) inhibitors;
- (cc) IMPDH inhibitors;
- (dd) adhesion molecule inhibitors, including VLA-4 antagonists;
- (ee) cathepsins;
- (ff) MAP kinase inhibitors;
- (gg) glucose 6-phosphate dehydrogenase inhibitors;
- (hh) kinin B₁ and B₂ receptor antagonists;
- (ii) gold in the form of an aurothio group together with various hydrophilic groups;

- (jj) immunosuppressive agents selected from the group consisting of cyclosporine, azathioprine and methotrexate;
- (kk) anti-gout agents selected from the group consisting of colchicines;
- (ll) xanthine oxidase inhibitors selected from the group consisting of allopurinol;
- (mm) uricosuric agents selected from the group consisting of probenecid, sulfinpyrazone and benzbromarone;
- (nn) antineoplastic agents, which are antimitotic medicaments selected from the group consisting of vinblastine and vincristine;
- (oo) agents for promoting growth hormone secretion;
- (pp) inhibitors of matrix metalloproteases (MMPs) selected from the group consisting of stromelysins, collagenases, gelatinases, aggrecanase, collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) and stromelysin-3 (MMP-11);
- (qq) transforming growth factor (TGF β);
- (rr) platelet-derived growth factor (PDGF);
- (ss) fibroblast growth factor selected from the group consisting of basic fibroblast growth factor (bFGF);
- (tt) granulocyte macrophage colony stimulating factor (GM-CSF);
- (uu) capsaicin;

(vv) tachykinin NK₁ and NK₃ receptor antagonists selected from the group consisting of NKP-608C, SB233412 (talnetant) and D-4418;

(ww) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892;

and

(xx) adenosine A2a receptor agonists.

Claims 31. -- 33. (Canceled)